The Adoption of Viral Capsid-Derived Virus-Like Particles (VLPs) for Disease Prevention and Treatments
Open Access
Abstract
In the present paper, Mohosen et alKeywords
This publication has 9 references indexed in Scilit:
- Pharmacological and non-pharmacological efforts at prevention, mitigation, and treatment for COVID-19Journal of Drug Targeting, 2020
- The race for coronavirus vaccines: a graphical guideNature, 2020
- Development of Human Monoclonal Antibody for Claudin-3 Overexpressing Carcinoma TargetingBiomolecules, 2019
- VLPs Derived from the CCMV Plant Virus Can Directly Transfect and Deliver Heterologous Genes for Translation into Mammalian CellsBioMed Research International, 2019
- Interaction of Viral Capsid-Derived Virus-Like Particles (VLPs) with the Innate Immune SystemVaccines, 2018
- The role of human papillomavirus vaccines in cervical cancer: Prevention and treatmentCritical Reviews in Oncology/Hematology, 2018
- Major findings and recent advances in virus–like particle (VLP)-based vaccinesSeminars in Immunology, 2017
- Immunity to α-Gal: Toward a Single-Antigen Pan-Vaccine To Control Major Infectious Diseases2017
- Virus-like Particle Display of the α-Gal Carbohydrate for Vaccination against Leishmania InfectionACS Central Science, 2017